Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur J Med Chem ; 168: 176-188, 2019 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-30818177

RESUMO

The synthesis and evaluation of a series of N,N-bis-heterocyclic-methylamines 1 as isoazaerianin analogues are described. It was demonstrated that the replacement of the 3,4,5-trimethoxyphenyl A-ring present in CA-4, isoCA-4 and isoazaerianin by a quinoline or a quinazoline ring is possible and often beneficiary for a high level of cytotoxicity. We have also showed that a carbazole or an indole nucleus are very effective as B-rings in this series, leading to anti-cancer drugs 1 having a sub-nanomolar level of cytotoxicity (1a: IC50 = 70 pM against HCT116 cells). 1a also display a high level of cytotoxicity against four other human cancer cells and inhibited tubulin assembly at a micromolar level. Moreover, at a concentration of 5 nM, 1a arrested the cellular cycle in G2/M phase of the cellular cycle and induced apoptosis of HCT116 cells. It was also showed that after few hours 1a at a concentration of 10 nM totally disrupted endothelial network formation on Matrigel.


Assuntos
Antineoplásicos/farmacologia , Citotoxinas/farmacologia , Metilaminas/farmacologia , Mitose/efeitos dos fármacos , Antineoplásicos/síntese química , Antineoplásicos/química , Apoptose/efeitos dos fármacos , Pontos de Checagem do Ciclo Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Citotoxinas/síntese química , Citotoxinas/química , Relação Dose-Resposta a Droga , Ensaios de Seleção de Medicamentos Antitumorais , Células HCT116 , Humanos , Metilaminas/síntese química , Metilaminas/química , Estrutura Molecular , Relação Estrutura-Atividade , Células Tumorais Cultivadas
2.
Fitoterapia ; 131: 91-95, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-30342177

RESUMO

N-myristoylation (Myr) is an eukaryotic N-terminal co- or post-translational protein modification in which the enzyme N-myristoyltransferase (NMT) transfers a fatty acid (C14:0) to the N-terminal glycine residues of several cellular key proteins. Depending on the cellular context, NMT may serve as a molecular target in anticancer or anti-infectious therapy, and drugs that inhibit this enzyme may be useful in the treatment of cancer or infectious diseases. As part of an on-going project to identify natural Homo sapiens N-myristoyltransferase 1 inhibitors (HsNMT1), two ellagitannins, punicalagin (1) and isoterchebulin (2), along with eschweilenol C (3) and ellagic acid (4) were isolated from the bark of Terminalia bentzoë (L.) L. f. subsp. bentzoë. Their structures were determined by means of spectroscopic analyses and comparison with literature data. Punicalagin (1) and isoterchebulin (2) showed significant inhibitory activity towards HsNMT1, and also against Plasmodium falciparum NMT (PfNMT) both in vitro and in cellulo, opening alternative paths for new NMT inhibitors development. This is the first report identifying natural products from a botanical source as inhibitors of HsNMT and PfNMT.


Assuntos
Aciltransferases/antagonistas & inibidores , Taninos Hidrolisáveis/farmacologia , Terminalia/química , Linhagem Celular Tumoral , França , Humanos , Taninos Hidrolisáveis/isolamento & purificação , Estrutura Molecular , Compostos Fitoquímicos/isolamento & purificação , Compostos Fitoquímicos/farmacologia , Casca de Planta/química , Plasmodium falciparum/efeitos dos fármacos , Reunião
3.
J Med Chem ; 61(20): 9386-9392, 2018 10 25.
Artigo em Inglês | MEDLINE | ID: mdl-30221935

RESUMO

3,3'-Spirocyclopentene oxindoles structurally related to Wang's spiropyrrolidine oxindoles have been highlighted as a new class of antiproliferative agents against cancer cell lines with wild-type p53 status (IC50 up to 0.96 µM on SJSA-1 and 2.9 µM in HCT116 p53-wt). Inhibition of the MDM2-p53 interactions has been demonstrated through in vitro HTRF assays (IC50 up to 3.1 nM), while Western blot analysis showed activation of p53 selectively in HCT116 cancer cell lines with wild-type p53.


Assuntos
Antineoplásicos/química , Antineoplásicos/farmacologia , Oxindóis/química , Oxindóis/farmacologia , Proteínas Proto-Oncogênicas c-mdm2/metabolismo , Compostos de Espiro/química , Proteína Supressora de Tumor p53/metabolismo , Proliferação de Células/efeitos dos fármacos , Desenho de Fármacos , Células HCT116 , Humanos , Modelos Moleculares , Conformação Molecular , Ligação Proteica/efeitos dos fármacos , Relação Estrutura-Atividade
4.
Cancer Res ; 78(18): 5384-5397, 2018 09 15.
Artigo em Inglês | MEDLINE | ID: mdl-30054335

RESUMO

The mTOR is a central regulator of cell growth and is highly activated in cancer cells to allow rapid tumor growth. The use of mTOR inhibitors as anticancer therapy has been approved for some types of tumors, albeit with modest results. We recently reported the synthesis of ICSN3250, a halitulin analogue with enhanced cytotoxicity. We report here that ICSN3250 is a specific mTOR inhibitor that operates through a mechanism distinct from those described for previous mTOR inhibitors. ICSN3250 competed with and displaced phosphatidic acid from the FRB domain in mTOR, thus preventing mTOR activation and leading to cytotoxicity. Docking and molecular dynamics simulations evidenced not only the high conformational plasticity of the FRB domain, but also the specific interactions of both ICSN3250 and phosphatidic acid with the FRB domain in mTOR. Furthermore, ICSN3250 toxicity was shown to act specifically in cancer cells, as noncancer cells showed up to 100-fold less sensitivity to ICSN3250, in contrast to other mTOR inhibitors that did not show selectivity. Thus, our results define ICSN3250 as a new class of mTOR inhibitors that specifically targets cancer cells.Significance: ICSN3250 defines a new class of mTORC1 inhibitors that displaces phosphatidic acid at the FRB domain of mTOR, inducing cell death specifically in cancer cells but not in noncancer cells. Cancer Res; 78(18); 5384-97. ©2018 AACR.


Assuntos
Neoplasias/metabolismo , Ácidos Fosfatídicos/metabolismo , Serina-Treonina Quinases TOR/metabolismo , Animais , Ciclo Celular , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular , Técnicas de Cocultura , Fibroblastos/metabolismo , Células HCT116 , Compostos Heterocíclicos de 4 ou mais Anéis/química , Compostos Heterocíclicos de 4 ou mais Anéis/farmacologia , Humanos , Células K562 , Camundongos , Modelos Moleculares , Simulação de Dinâmica Molecular , Conformação Proteica , Inibidores de Proteínas Quinases/farmacologia
5.
J Med Chem ; 60(20): 8358-8368, 2017 10 26.
Artigo em Inglês | MEDLINE | ID: mdl-28895732

RESUMO

Ferrociphenols are known to display anticancer properties by original mechanisms dependent on redox properties and generation of active metabolites such as quinone methides. Recent studies have highlighted the positive impact of oxidative stress on chemosensitivity and prognosis of ovarian cancer patients. Ovarian adenocarcinomas are shown to be an excellent model for defining the impact of selected ferrociphenols as new therapeutic drugs for such cancers. This work describes the syntheses and preliminary mechanistic research of unprecedented multitargeting heterocyclic ferrociphenols bearing either a succinimidyl or phthalimidyl group that show exceptional antiproliferative behavior against epithelial ovarian cancer cells resistant to cisplatin. Owing to the failure of the present pharmaceutical options, such as carboplatin a metallodrug based on Pt coordination chemistry, these species may help to overcome the problem of lethal resistance. Currently, ferrociphenolic entities generally operate via apoptotic and senescence pathways. We present here our first results in this new cyclic-imide series.


Assuntos
Proliferação de Células/efeitos dos fármacos , Cisplatino/farmacologia , Compostos Heterocíclicos/farmacologia , Neoplasias Ovarianas/patologia , Fenóis/farmacologia , Apoptose/efeitos dos fármacos , Ciclo Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Resistencia a Medicamentos Antineoplásicos , Ensaios de Seleção de Medicamentos Antitumorais , Feminino , Compostos Heterocíclicos/química , Humanos , Fenóis/química , Análise Espectral
6.
J Med Chem ; 59(23): 10774-10780, 2016 12 08.
Artigo em Inglês | MEDLINE | ID: mdl-27753480

RESUMO

The first example of vinca derivatives 16-18 able to modulate P-glycoprotein (Pgp) efflux activity is reported. They were elaborated in two steps from vinorelbine 3 (VLN) by a modification of the velbenamine moiety. These compounds were able to decrease efficiently Pgp mediated influx and efflux of rhodamine-123 (Rho) and to restore the cytotoxicity of vinorelbine 3 (VLN) and doxorubicin (Dox) on K562R (dox-resistant) cell lines.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/antagonistas & inibidores , Doxorrubicina/farmacologia , Rodamina 123/farmacologia , Vimblastina/análogos & derivados , Vinca/química , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Relação Dose-Resposta a Droga , Doxorrubicina/química , Doxorrubicina/isolamento & purificação , Humanos , Células K562 , Estrutura Molecular , Rodamina 123/química , Rodamina 123/isolamento & purificação , Relação Estrutura-Atividade , Vimblastina/química , Vimblastina/isolamento & purificação , Vimblastina/farmacologia , Vinorelbina
7.
J Med Chem ; 57(12): 5470-6, 2014 Jun 26.
Artigo em Inglês | MEDLINE | ID: mdl-24871162

RESUMO

Hybrids of vinca alkaloids and phomopsin A have been elaborated with the aim of interfering with the "vinca site" and the "peptide site" of the vinca domain in tubulin. They were synthesized by an efficient one-pot procedure that directly links the octahydrophomopsin lateral chain to the velbenamine moiety of 7'-homo-anhydrovinblastine. In their modeled complexes with tubulin, these hybrids were found to superimpose nicely on the tubulin-bound structures of vinblastine and phomopsin A. This good matching can account for the fact that two of them are very potent inhibitors of microtubules assembly and are cytotoxic against four cancer cell lines.


Assuntos
Antineoplásicos/síntese química , Micotoxinas/síntese química , Vimblastina/análogos & derivados , Vimblastina/síntese química , Antineoplásicos/química , Antineoplásicos/farmacologia , Linhagem Celular Tumoral , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Modelos Moleculares , Micotoxinas/química , Micotoxinas/farmacologia , Tubulina (Proteína)/química , Moduladores de Tubulina/síntese química , Moduladores de Tubulina/química , Moduladores de Tubulina/farmacologia , Vimblastina/química , Vimblastina/farmacologia
8.
Org Biomol Chem ; 12(9): 1518-24, 2014 Mar 07.
Artigo em Inglês | MEDLINE | ID: mdl-24448828

RESUMO

A short synthesis of N-substituted 3,4-diarylpyrroles by condensation of a phenacyl halide with a primary amine and a phenylacetaldehyde is reported. The key step is an intramolecular cyclization of an in situ generated enamine onto a ketone. Using differently substituted aromatic reactants and N-(3-aminopropyl)azatricyclodecane as the amine component, the preparation of analogs of the cytotoxic marine alkaloid halitulin could be achieved. The cytotoxicity of some of the compounds obtained by this method was studied, and one of them proved to be a very potent derivative, acting at a nanomolar concentration, in a caspase-independent cell death mechanism.


Assuntos
Antineoplásicos/farmacologia , Pirróis/farmacologia , Antineoplásicos/síntese química , Antineoplásicos/química , Morte Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Relação Dose-Resposta a Droga , Ensaios de Seleção de Medicamentos Antitumorais , Células HCT116 , Humanos , Células K562 , Estrutura Molecular , Pirróis/síntese química , Pirróis/química , Relação Estrutura-Atividade
9.
J Med Chem ; 56(15): 6088-100, 2013 Aug 08.
Artigo em Inglês | MEDLINE | ID: mdl-23822556

RESUMO

Sixteen new 7'-homo-anhydrovinblastine derivatives were prepared in one or two steps from vinorelbine by means of an original and regiospecific rearrangement and subsequent diastereoselective reduction. This strategy has allowed fast access to a family of vinca alkaloid derivatives with an enlarged and functionalized ring C'. Their synthesis and biological evaluation are reported. One compound (compound 35) is 1.7 times more active than vinorelbine as a tubulin assembly inhibitor. Moreover, some of these compounds are highly cytotoxic, and two of them are more potent than vinorelbine on HCT116 and K562 cell lines. Molecular modeling studies, carried out with two of the new vinca derivatives, provide useful hints about how a given functionalization introduced at positions 7' and 8' of the C' ring results in improved binding interactions between one of the new derivatives and the interdimer interface when compared to the parent compound vinblastine.


Assuntos
Antineoplásicos/síntese química , Moduladores de Tubulina/síntese química , Vimblastina/análogos & derivados , Vimblastina/síntese química , Antineoplásicos/farmacologia , Ciclo Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Microtúbulos/química , Modelos Moleculares , Estereoisomerismo , Relação Estrutura-Atividade , Moduladores de Tubulina/farmacologia , Vimblastina/farmacologia
10.
Anal Methods ; 3(3): 678-682, 2011 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-32938090

RESUMO

Fast and reproducible quantification of thymosins ß4 and ß10 in different cell cultures was achieved by ultra high performance liquid chromatography coupled to mass spectrometry. We demonstrated that cancer cell lines all exhibit a higher amount of Tß10 compared to control cells, whereas the level of Tß4 is drastically depending on cell lines.

11.
Ann N Y Acad Sci ; 1194: 53-9, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20536450

RESUMO

The natural tetrapeptide acetyl-ser-asp-lys-pro (AcSDKP) is formed in vivo by enzymatic cleavage of the N terminus of thymosin beta4 by prolyl oligopeptidase (POP). Recently, AcSDKP was shown to promote angiogenesis. Because of the critical role of neovascularization in cancer development, the levels of AcSDKP and POP activity in a number of different malignant tissues were investigated. Our studies revealed that AcSDKP levels were markedly elevated in neoplastic diseases including hematologic malignancies and solid neoplasms. Consistent with this finding, the enhanced activity of POP was also detected in all analyzed specimens of cancer tissues. Both these novel findings are in concert with the previously reported overexpression of thymosin beta4 in a large variety of malignant tumors and with its potential role in cancerogenesis. The physiological relevance of these findings awaits further studies; however, our first results strongly suggest a key role for AcSDKP in the pathogenesis of cancer.


Assuntos
Dipeptídeos/metabolismo , Neoplasias/metabolismo , Oligopeptídeos/fisiologia , Serina Endopeptidases/metabolismo , Animais , Fenômenos Bioquímicos , Camundongos , Neoplasias/sangue , Neoplasias/enzimologia , Neovascularização Patológica , Prolil Oligopeptidases , Timosina
12.
Bioorg Med Chem ; 17(6): 2310-20, 2009 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-19261478

RESUMO

2,3-Diaminopropionic acid (Dap) and N-terminal Dap peptides have been found to inhibit in vitro protein-modifications by methylglyoxal (MG), one of the highly reactive alpha-dicarbonyl compounds. MG scavenging potency of the newly synthesized N-terminal Dap peptides is demonstrated by RP-HPLC, SDS-PAGE and non-denaturing PAGE analysis, assays for enzymatic activity and cell viability study and was compared with that of known AGE inhibitors, such as aminoguanidine, pyridoxamine, metformin and carnosine. Two addition products of MG and L-Dap-L-Leu are separated by HPLC and their chemical structures are characterized by (1)H and (13)C NMR spectroscopy to indicate that both of them are pyrazines derived from 2 molecules of MG and 1 molecule of L-Dap-L-Leu. Mutagenic activities of L-Dap-L-Leu and L-Dap-L-Val and their metabolites according to the Ames assay are found to be negative.


Assuntos
Produtos Finais de Glicação Avançada/antagonistas & inibidores , Peptídeos/química , Aldeído Pirúvico/química , beta-Alanina/análogos & derivados , Cromatografia Líquida de Alta Pressão , Eletroforese em Gel de Poliacrilamida , Espectroscopia de Ressonância Magnética , beta-Alanina/química
13.
Antimicrob Agents Chemother ; 53(3): 1100-6, 2009 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-19015354

RESUMO

Malaria is one of the most significant causes of infectious disease in the world. The search for new antimalarial chemotherapies has become increasingly urgent due to the parasites' resistance to current drugs. Ellagic acid is a polyphenol found in various plant products. In this study, antimalarial properties of ellagic acid were explored. The results obtained have shown high activity in vitro against all Plasmodium falciparum strains whatever their levels of chloroquine and mefloquine resistance (50% inhibitory concentrations ranging from 105 to 330 nM). Ellagic acid was also active in vivo against Plamodium vinckei petteri in suppressive, curative, and prophylactic murine tests, without any toxicity (50% effective dose by the intraperitoneal route inferior to 1 mg/kg/day). The study of the point of action of its antimalarial activity in the erythrocytic cycle of Plasmodium falciparum demonstrated that it occurred at the mature trophozoite and young schizont stages. Moreover, ellagic acid has been shown to potentiate the activity of current antimalarial drugs such as chloroquine, mefloquine, artesunate, and atovaquone. This study also proved the antioxidant activity of ellagic acid and, in contrast, the inhibitory effect of the antioxidant compound N-acetyl-l-cysteine on its antimalarial efficacy. The possible mechanisms of action of ellagic acid on P. falciparum are discussed in light of the results. Ellagic acid has in vivo activity against plasmodia, but modification of the compound could lead to improved pharmacological properties, principally for the oral route.


Assuntos
Antimaláricos/farmacologia , Ácido Elágico/farmacologia , Malária Falciparum/tratamento farmacológico , Parasitemia/tratamento farmacológico , Plasmodium falciparum/efeitos dos fármacos , Plasmodium/efeitos dos fármacos , Animais , Antimaláricos/efeitos adversos , Antimaláricos/uso terapêutico , Artemisininas/farmacologia , Artemisininas/uso terapêutico , Artesunato , Atovaquona/farmacologia , Atovaquona/uso terapêutico , Cloroquina/farmacologia , Cloroquina/uso terapêutico , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Ácido Elágico/efeitos adversos , Ácido Elágico/química , Ácido Elágico/uso terapêutico , Eritrócitos/efeitos dos fármacos , Eritrócitos/parasitologia , Feminino , Concentração Inibidora 50 , Mefloquina/farmacologia , Mefloquina/uso terapêutico , Camundongos , Camundongos Endogâmicos , Estrutura Molecular , Peso Molecular , Testes de Sensibilidade Parasitária , Plasmodium falciparum/genética , Esquizontes/efeitos dos fármacos , Esquizontes/parasitologia , Trofozoítos/efeitos dos fármacos , Trofozoítos/parasitologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...